Showing results (1-10 of 55) with videos related to
Sort By:
Pageof 6
Surgery Today|May 1, 2015
Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC)Fumihiro Tanaka, Kazue YonedaLung Cancer (Auckland, N.Z.)|February 18, 2017
Circulating tumor cells (CTCs) in lung cancer: current status and future perspectivesFumihiro Tanaka, Kazue Yoneda, Seiki HasegawaJournal of UOEH|June 22, 2018
Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC)Kazue Yoneda, Naoko Imanishi, Yoshinobu Ichiki, et al.Oncology Reports|November 15, 2016
EpCAM-independent capture of circulating tumor cells with a 'universal CTC-chip'Yasuhiro Chikaishi, Kazue Yoneda, Takashi Ohnaga, et al.Journal of UOEH|July 12, 2019
Treatment of Non-small Cell Lung Cancer with EGFR-mutationsKazue Yoneda, Naoko Imanishi, Yoshinobu Ichiki, et al.Surgery Today|April 13, 2018
A liquid biopsy in primary lung cancerKazue Yoneda, Naoko Imanishi, Yoshinobu Ichiki, et al.Oncology Letters|February 14, 2018
Capture of mesothelioma cells with 'universal' CTC-chipKazue Yoneda, Yasuhiro Chikaishi, Taiji Kuwata, et al.The Journal of Thoracic and Cardiovascular Surgery|July 17, 2017
Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lungAyako Hirai, Kazue Yoneda, Shohei Shimajiri, et al.Case Reports in Oncology|April 18, 2017
Circulating Tumor Cell Count Can Be a Useful Prognostic Factor in Lung Resection via Cardiopulmonary BypassMasaki Hashimoto, Yoshitomo Okumura, Fumihiro Tanaka, et al.Immunology Letters|January 26, 2018
Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancerMasahiro Takeuchi, Tomomitsu Doi, Kunie Obayashi, et al.Pageof 6